Compare BNR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNR | UNCY |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.9M | 126.4M |
| IPO Year | 2020 | 2021 |
| Metric | BNR | UNCY |
|---|---|---|
| Price | $20.08 | $5.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 53.2K | ★ 360.0K |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,749,382.00 | N/A |
| Revenue This Year | $136.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.56 | N/A |
| 52 Week Low | $2.18 | $3.71 |
| 52 Week High | $24.48 | $11.00 |
| Indicator | BNR | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 46.20 |
| Support Level | $19.59 | $5.36 |
| Resistance Level | $21.07 | $5.95 |
| Average True Range (ATR) | 2.23 | 0.33 |
| MACD | -0.15 | -0.06 |
| Stochastic Oscillator | 39.11 | 23.16 |
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.